{"id":38664,"date":"2025-08-06T12:55:40","date_gmt":"2025-08-06T04:55:40","guid":{"rendered":"https:\/\/flcube.com\/?p=38664"},"modified":"2025-08-06T12:55:40","modified_gmt":"2025-08-06T04:55:40","slug":"everest-medicines-nefecon-granted-full-approval-by-taiwans-tfda-for-iga-nephropathy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38664","title":{"rendered":"Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy"},"content":{"rendered":"\n

China-based Everest Medicines (HKG: 1952<\/a>) announced today that the Taiwan Food and Drug Administration (TFDA) has granted full approval for the supplemental application of Nefecon (budesonide delayed-release capsules). Nefecon is indicated to reduce the decline in kidney function in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression.<\/p>\n\n\n\n

Regulatory Approval Details<\/strong>
This full approval removes the previous condition in the product label that required submitting the complete confirmatory trial analysis to demonstrate clinical benefits. With this approval, Nefecon has now achieved full approval across all of Everest Medicines’ licensed territories, including mainland China, Singapore, Hong Kong, Macau, and South Korea.<\/p>\n\n\n\n

Product Overview<\/strong>
Nefecon is an oral, delayed-release capsule formulation of budesonide. It was developed to target the reduction of disease progression in patients with primary IgA nephropathy. The drug has demonstrated significant clinical benefits in reducing the decline of kidney function in affected adults.<\/p>\n\n\n\n

Licensing and Expansion<\/strong>
In June 2019, Everest Medicines entered into an exclusive licensing agreement with Calliditas to develop and commercialize Nefecon in Greater China and Singapore. This agreement was expanded in March 2022 to include South Korea within Everest’s licensed territory. With this latest approval, Nefecon reinforces its position as a key treatment option for IgA nephropathy across Asia.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA)…<\/p>\n","protected":false},"author":1,"featured_media":38666,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[126,1164,15],"class_list":["post-38664","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-everest-medicines","tag-hkg-1952","tag-product-approvals"],"yoast_head":"\nEverest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for IgA Nephropathy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA) has granted full approval for the supplemental application of Nefecon (budesonide delayed-release capsules). Nefecon is indicated to reduce the decline in kidney function in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38664\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for IgA Nephropathy\" \/>\n<meta property=\"og:description\" content=\"China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA) has granted full approval for the supplemental application of Nefecon (budesonide delayed-release capsules). Nefecon is indicated to reduce the decline in kidney function in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38664\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-06T04:55:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy\",\"datePublished\":\"2025-08-06T04:55:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664\"},\"wordCount\":223,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0603.webp\",\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38664#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38664\",\"name\":\"Everest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for IgA Nephropathy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0603.webp\",\"datePublished\":\"2025-08-06T04:55:40+00:00\",\"description\":\"China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA) has granted full approval for the supplemental application of Nefecon (budesonide delayed-release capsules). Nefecon is indicated to reduce the decline in kidney function in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38664\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for IgA Nephropathy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38664#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for IgA Nephropathy - Insight, China's Pharmaceutical Industry","description":"China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA) has granted full approval for the supplemental application of Nefecon (budesonide delayed-release capsules). Nefecon is indicated to reduce the decline in kidney function in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38664","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for IgA Nephropathy","og_description":"China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA) has granted full approval for the supplemental application of Nefecon (budesonide delayed-release capsules). Nefecon is indicated to reduce the decline in kidney function in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression.","og_url":"https:\/\/flcube.com\/?p=38664","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-06T04:55:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38664#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38664"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy","datePublished":"2025-08-06T04:55:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38664"},"wordCount":223,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38664#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0603.webp","keywords":["Everest Medicines","HKG: 1952","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38664#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38664","url":"https:\/\/flcube.com\/?p=38664","name":"Everest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for IgA Nephropathy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38664#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38664#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0603.webp","datePublished":"2025-08-06T04:55:40+00:00","description":"China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA) has granted full approval for the supplemental application of Nefecon (budesonide delayed-release capsules). Nefecon is indicated to reduce the decline in kidney function in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38664#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38664"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38664#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0603.webp","width":1080,"height":608,"caption":"Everest Medicines' Nefecon Granted Full Approval by Taiwan's TFDA for IgA Nephropathy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38664#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38664"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38664\/revisions"}],"predecessor-version":[{"id":38667,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38664\/revisions\/38667"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38666"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}